Lightbridge Corp.

LTBR

Lightbridge Corporation (LTBR) is a nuclear fuel technology company focused on developing and commercializing next-generation metallic nuclear fuels. The company aims to enhance the safety, performance, and economics of nuclear power plants through its innovative fuel designs, which are intended to enable longer fuel cycles and reduce waste. Lightbridge's research and development efforts target both existing and new nuclear reactor technologies worldwide.

$17.14 +0.26 (1.52%)
🚫 Lightbridge Corp. does not pay dividends

Company News

Lightbridge Announces Start of Irradiation Testing of its Enriched Uranium-Zirconium Alloy Samples in Advanced Test Reactor at Idaho National Laboratory
GlobeNewswire Inc. • Lightbridge Corporation • November 19, 2025

Lightbridge Corporation has begun irradiation testing of its enriched uranium-zirconium alloy fuel material samples at Idaho National Laboratory's Advanced Test Reactor, marking a significant milestone in its nuclear fuel technology development program.

Nuclear Stocks Are Melting Down—Should Investors Panic?
Investing.com • Jordan Chussler • November 12, 2025

Nuclear stocks experienced significant sell-offs last week, driven by broader market corrections in AI-related stocks and investors taking profits. Despite short-term volatility, underlying trends in nuclear energy and AI infrastructure remain promising.

If You'd Invested $10,000 in Oklo Stock 1 Year Ago, Here's How Much You'd Have Today
The Motley Fool • Neha Chamaria • September 16, 2025

Oklo, a nuclear energy startup, saw an extraordinary 1,400% stock gain in one year, driven by growing interest in nuclear power and potential AI data center energy demands.

48 Biggest Movers From Friday
Benzinga • Lisa Levin • May 24, 2021

Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares surged 127.3% to close at $60.00 on Friday after the company announced new results from a Phase 2 study evaluating its lead drug candidate, ANVS401, for Alzheimer's disease (AD), Parkinson's disease (PD). Participants treated with ANVS401 for 25 days showed statistically significant cognitive impro...

Related Companies